CLASS II Device recall · Reported 14 Apr 2021 · FDA Enforcement Report

BD BBL Martin-Lewis Agar, 100 Ea recalled by Becton Dickinson &

Becton Dickinson is recalling BD BBL Martin-Lewis Agar, 100 Ea, distributed nationwide in the US. The recall was initiated on 17 Mar 2021 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot Numbers: 0317559 Exp. Date 2021-MAR-11; 0345695 Exp. Date 2021-APR-06 UDI: 01)30382902215586 (10)0317559(17)031121 (30)0100 (01)30382902215586 (10)0345695(17)040621 (30)0100
Quantity recalled15550 EA

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1377-2021
FDA event ID
87546
Recalling firm
Becton Dickinson, Sparks, MD
Classification
Class II
Status
Terminated
Recall initiated
17 Mar 2021
FDA classified
8 Apr 2021
Reported
14 Apr 2021
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

17 Mar 2021Recall initiated by company
8 Apr 2021Classified by FDA+22 days
14 Apr 2021Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Products show heavy growth of C. albicans after 24 hours of incubation due to misformulation (expected reaction is partial inhibition after 18-48 hours incubation) and reduce the identification of Neisseria contributing to a delay in time to definitive diagnosis or a delay in proper treatment

Product as listed by the FDA

BD BBL Martin-Lewis Agar, 100 Ea - Product Usage: used for the isolation of pathogenic Neisseria from specimens containing mixed flora of bacteria and fungi. Catalog Number: 221558

Where it was distributed

Worldwide distribution - US Nationwide distribution and the countries of Canada, Korea.

Nationwide

Questions about this recall

Why was it recalled?

Products show heavy growth of C. albicans after 24 hours of incubation due to misformulation (expected reaction is partial inhibition after 18-48 hours incubation) and reduce the identification of Neisseria contributing to a delay in time to definitive diagnosis or a delay in proper treatment

Which lots are affected?

Lot Numbers: 0317559 Exp. Date 2021-MAR-11; 0345695 Exp. Date 2021-APR-06 UDI: 01)30382902215586 (10)0317559(17)031121 (30)0100 (01)30382902215586 (10)0345695(17)040621 (30)0100

Where was it sold?

Worldwide distribution - US Nationwide distribution and the countries of Canada, Korea.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 87546
ReportedClassRecallCompanyReasonWhere
CLASS IIBD BBL Martin-Lewis Agar 20 Ea recalled by Becton Dickinson &Becton DickinsonOtherNationwide

More recalls from Becton Dickinson

All 364

Other Other Medical Devices recalls

All 13,778